Laboratory Co. of America Holdings (NYSE:LH - Free Report) - Equities researchers at Leerink Partnrs reduced their Q1 2025 earnings per share (EPS) estimates for shares of Laboratory Co. of America in a note issued to investors on Friday, April 4th. Leerink Partnrs analyst M. Cherny now expects that the medical research company will earn $3.65 per share for the quarter, down from their prior estimate of $3.67. The consensus estimate for Laboratory Co. of America's current full-year earnings is $16.01 per share. Leerink Partnrs also issued estimates for Laboratory Co. of America's Q2 2025 earnings at $4.11 EPS, Q4 2025 earnings at $4.10 EPS, FY2025 earnings at $16.06 EPS and FY2027 earnings at $19.86 EPS.
Laboratory Co. of America (NYSE:LH - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%.
Several other brokerages have also commented on LH. Morgan Stanley raised their price target on shares of Laboratory Co. of America from $260.00 to $270.00 and gave the company an "overweight" rating in a research note on Tuesday, December 17th. UBS Group cut their target price on Laboratory Co. of America from $293.00 to $286.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. Bank of America increased their price target on Laboratory Co. of America from $262.00 to $271.00 and gave the stock a "buy" rating in a research note on Friday, December 13th. Redburn Atlantic assumed coverage on shares of Laboratory Co. of America in a research note on Wednesday, April 2nd. They set a "buy" rating and a $276.00 price objective on the stock. Finally, Citigroup upgraded shares of Laboratory Co. of America from a "neutral" rating to a "buy" rating and increased their target price for the company from $250.00 to $300.00 in a research report on Tuesday, March 4th. Three equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $268.77.
Read Our Latest Report on Laboratory Co. of America
Laboratory Co. of America Stock Performance
NYSE:LH traded up $2.85 during mid-day trading on Monday, hitting $221.46. The stock had a trading volume of 1,031,685 shares, compared to its average volume of 638,269. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.67. The company has a 50 day simple moving average of $240.04 and a 200-day simple moving average of $234.81. The stock has a market capitalization of $18.54 billion, a price-to-earnings ratio of 25.11, a P/E/G ratio of 1.71 and a beta of 0.99. Laboratory Co. of America has a 52 week low of $191.97 and a 52 week high of $258.59.
Laboratory Co. of America Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 11th. Shareholders of record on Thursday, May 29th will be given a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 1.30%. Laboratory Co. of America's dividend payout ratio (DPR) is 32.65%.
Insider Buying and Selling at Laboratory Co. of America
In other Laboratory Co. of America news, EVP Amy B. Summy sold 758 shares of the business's stock in a transaction dated Friday, March 28th. The stock was sold at an average price of $231.67, for a total transaction of $175,605.86. Following the sale, the executive vice president now owns 5,302 shares in the company, valued at approximately $1,228,314.34. The trade was a 12.51 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Adam H. Schechter sold 6,121 shares of the company's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $244.62, for a total transaction of $1,497,319.02. Following the sale, the chief executive officer now directly owns 86,445 shares of the company's stock, valued at $21,146,175.90. This represents a 6.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 14,258 shares of company stock valued at $3,518,177. Corporate insiders own 0.85% of the company's stock.
Hedge Funds Weigh In On Laboratory Co. of America
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Capital City Trust Co. FL grew its holdings in shares of Laboratory Co. of America by 1.5% during the fourth quarter. Capital City Trust Co. FL now owns 15,553 shares of the medical research company's stock valued at $3,567,000 after buying an additional 223 shares in the last quarter. Wealthcare Advisory Partners LLC grew its stake in Laboratory Co. of America by 23.9% during the 4th quarter. Wealthcare Advisory Partners LLC now owns 2,543 shares of the medical research company's stock valued at $583,000 after acquiring an additional 490 shares in the last quarter. Bryn Mawr Capital Management LLC grew its stake in Laboratory Co. of America by 51.2% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 1,495 shares of the medical research company's stock valued at $343,000 after acquiring an additional 506 shares in the last quarter. Barclays PLC increased its holdings in shares of Laboratory Co. of America by 11.8% in the 3rd quarter. Barclays PLC now owns 620,721 shares of the medical research company's stock valued at $138,718,000 after purchasing an additional 65,356 shares during the period. Finally, Nordea Investment Management AB lifted its position in shares of Laboratory Co. of America by 7.0% in the fourth quarter. Nordea Investment Management AB now owns 1,052,927 shares of the medical research company's stock worth $243,321,000 after purchasing an additional 68,974 shares in the last quarter. 95.94% of the stock is currently owned by hedge funds and other institutional investors.
Laboratory Co. of America Company Profile
(
Get Free Report)
Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
Further Reading
Before you consider Laboratory Co. of America, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Laboratory Co. of America wasn't on the list.
While Laboratory Co. of America currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
